


Product Name : Acalabrutinib
Cat. No. : PC-45383
CAS No. : 1420477-60-6
Molecular Formula : C₂₆H₂₃N₇O₂
Molecular Weight : 465.5065
Target : BTK
Solubility : DMSO: ≥ 31 mg/mL



Biological Activity

Acalabrutinib (ACP-196) is a potent, irreversible, covalent second-generation **BTK** inhibitor with IC₅₀ of 3 nM.

Acalabrutinib (ACP-196) is more potent and selective than ibrutinib, and does not inhibit EGFR, Itk or Txk.

Acalabrutinib (ACP-196) inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT, in the in vitro signaling assay on primary human CLL cells.

Acalabrutinib (ACP-196) inhibits anti-IgM-induced CD86 expression in CD19⁺ splenocytes with an ED₅₀ of 0.34 mg/kg in mice.

Acalabrutinib (ACP-196) has promising safety and efficacy profiles for CLL treatment; orally active.

References

Byrd JC, et al. *N Engl J Med*. 2016 Jan 28;374(4):323-32.

Herman SEM, et al. *Clin Cancer Res*. 2017 Jul 15;23(14):3734-3743.

Niemann CU, et al. *Clin Cancer Res*. 2017 Jun 23. pii: clincanres.0650.2017.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com